BMS-986242

BMS-986242 is an orally active, potent, and selective small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing dioxygenase enzyme involved in the regulation of immune responses in cancer. By inhibiting IDO1, BMS-986242 aims to enhance anti-tumor immunity by preventing the immunosuppressive effects mediated through tryptophan metabolism. It has demonstrated strong preclinical activity and was developed as a structurally differentiated clinical candidate for the treatment of various cancers, including metastatic melanoma and renal cell carcinoma. The drug was designed to perform comparably to linrodostat (BMS-986205) in both in vitro potency and in vivo pharmacodynamic effect[1][3][4][5].